Correlation of T- and B-cell parameters and MRD level with clinical response to blinatumomab treatment in MRD⁺ ALL patients. Sixteen patients responding with a complete molecular response in BM after the first treatment cycle are compared with 4 nonresponders. Statistical analyses are shown for (A) T-cell counts at baseline, (B) maximal T-cell counts reached during expansion, (C) the area under the T-cell curve above the respective baseline T-cell count, (D) the overall area under the T-cell curve regardless of the respective baseline T-cell count, (E) target B-cell counts at baseline, and (F) the tumor load in the BM before treatment as determined by patient-specific PCR. Bars give median values; brackets indicate P values. AUC indicates area under the curve and is used as a measure of T-cell exposure.